Successful trial of Phase III of nasal ‘BBV154’ COVID-19 vaccine: Bharat Biotech

0
Nasal 'BBV154' COVID-19 vaccine

Hyderabad: Bharat Biotech International Limited (BBIL) on Monday said that the nasal COVID-19 vaccine ‘BBV154’ has proved to be safe, well tolerated, and immunogenic in Phase III controlled clinical trials. The vaccine manufacturer said in a statement issued here that the first and second phases of clinical trials of the potential vaccine were successful.

BBV154 has been specially formulated to be administered through the nose. In addition to delivering a dose of the vaccine through the nose, it has been designed and developed to make it cost-effective for low- and middle-income countries. BBV154 has been developed in partnership with Washington University in St. Louis, according to the statement.

Bharat Biotech worked on the delivery system including pre-clinical safety assessment, large-scale manufacturing, formula, and clinical trials on humans. The central government partly funded product development and clinical trials under the Department of Biotechnology’s COVID Protection Program.

According to the statement, the effect of BBV154 as a primary dose (the initial two doses) and the effect of giving BBV154 at the third dose to those taking two initial doses of other Covid-19 vaccines were assessed.

nasal-vaccine

Suchitra K Illa, Joint Managing Director, Bharat Biotech said, “Today, on the occasion of Independence Day, we are proud to announce the successful completion of the clinical trial of BBV154 Intranasal Vaccine. We were committed and focused on innovation and product development and this is yet another milestone for Bharat Biotech’s multidisciplinary team.”

She said that “If approved, then the international vaccine will make it easier to carry out large-scale vaccination campaigns.”

Advertisement